China NT Pharma Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for China NT Pharma Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Mar 06
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking
Dec 29Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Oct 30Is China NT Pharma Group (HKG:1011) Using Too Much Debt?
Apr 13In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China NT Pharma Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 31 | -28 | 22 | 33 | N/A |
| 3/31/2024 | 19 | -31 | 30 | 42 | N/A |
| 12/31/2023 | 7 | -33 | 38 | 50 | N/A |
| 6/30/2023 | -113 | -27 | 19 | 23 | N/A |
| 3/31/2023 | -57 | -38 | 25 | 30 | N/A |
| 12/31/2022 | N/A | -50 | 32 | 36 | N/A |
| 9/30/2022 | 222 | -121 | -57 | -53 | N/A |
| 6/30/2022 | 236 | -175 | -145 | -143 | N/A |
| 3/31/2022 | 231 | -162 | -141 | -139 | N/A |
| 12/31/2021 | 227 | -150 | -136 | -135 | N/A |
| 9/30/2021 | 235 | -147 | N/A | N/A | N/A |
| 6/30/2021 | 244 | -145 | 9 | 31 | N/A |
| 3/31/2021 | 233 | -167 | 6 | 28 | N/A |
| 12/31/2020 | 222 | -189 | 2 | 26 | N/A |
| 9/30/2020 | 185 | -271 | N/A | N/A | N/A |
| 6/30/2020 | 149 | -353 | 103 | 158 | N/A |
| 3/31/2020 | 151 | -351 | 32 | 103 | N/A |
| 12/31/2019 | 153 | -350 | -39 | 48 | N/A |
| 9/30/2019 | 254 | -547 | N/A | N/A | N/A |
| 6/30/2019 | 354 | -744 | -355 | -227 | N/A |
| 3/31/2019 | 463 | -670 | -360 | -176 | N/A |
| 12/31/2018 | 572 | -596 | -365 | -124 | N/A |
| 9/30/2018 | 587 | -190 | N/A | N/A | N/A |
| 6/30/2018 | 602 | 216 | -336 | 153 | N/A |
| 3/31/2018 | 604 | 215 | N/A | 150 | N/A |
| 12/31/2017 | 605 | 214 | N/A | 148 | N/A |
| 6/30/2017 | 288 | 78 | N/A | 60 | N/A |
| 3/31/2017 | 324 | 52 | N/A | 40 | N/A |
| 12/31/2016 | 360 | 25 | N/A | 21 | N/A |
| 9/30/2016 | 884 | 109 | N/A | -3 | N/A |
| 6/30/2016 | 853 | 101 | N/A | -27 | N/A |
| 3/31/2016 | 850 | 94 | N/A | -62 | N/A |
| 12/31/2015 | 848 | 88 | N/A | -97 | N/A |
| 9/30/2015 | 843 | 62 | N/A | -69 | N/A |
| 6/30/2015 | 837 | 36 | N/A | -42 | N/A |
| 3/31/2015 | 851 | 19 | N/A | 16 | N/A |
| 12/31/2014 | 865 | 2 | N/A | 73 | N/A |
| 9/30/2014 | 750 | -118 | N/A | 97 | N/A |
| 6/30/2014 | 636 | -239 | N/A | 121 | N/A |
| 3/31/2014 | 695 | -456 | N/A | 41 | N/A |
| 12/31/2013 | 754 | -673 | N/A | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1011's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1011's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1011's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1011's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1011's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1011's Return on Equity is forecast to be high in 3 years time